COMP <GO>
DCOY vs JUNS // EV/EBITDA & P/E VALUATION
Decoy Therapeutics Inc. (NASDAQ) VS. Jupiter Neurosciences Inc. (NASDAQ) • 15-METRIC TALLY: DCOY 2
— JUNS 1
■ METRIC PARITY
LAST: $1.23 (+11.82%) • MKT CAP: $2.9M
valuation
—
LAST: $2.37 (-5.20%) • MKT CAP: $3.1M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DCOY VS. JUNS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DCOY | JUNS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 80.60% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | DCOY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.1 | 32.2 | +1.90 | DCOY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.9M | $3.1M | -$191.0K | JUNS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DCOY REV | JUNS REV | DCOY GROSS % | JUNS GROSS % | DCOY FCF | JUNS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $21.8K | — | 80.6% | -$4.8M | -$5.4M |
| FY 2024 | $0 | $0 | — | — | -$4.5M | -$3.9M |
| FY 2023 | $0 | $0 | — | — | -$12.8M | -$481.0K |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DCOY // BETA —
JUNS // BETA —